Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting pyruvate metabolism generates distinct CD8+ T cell responses to gammaherpesvirus and B lymphoma
Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood
Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood
View: Text | PDF
Research Article Immunology Metabolism

Targeting pyruvate metabolism generates distinct CD8+ T cell responses to gammaherpesvirus and B lymphoma

  • Text
  • PDF
Abstract

T cells rely on different metabolic pathways to differentiate into effector or memory cells, and metabolic intervention is a promising strategy to optimize T cell function for immunotherapy. Pyruvate dehydrogenase (PDH) is a nexus between glycolytic and mitochondrial metabolism, regulating pyruvate conversion to either lactate or acetyl-CoA. Here, we retrovirally transduced pyruvate dehydrogenase kinase 1 (PDK1) or pyruvate dehydrogenase phosphatase 1 (PDP1), which control PDH activity, into CD8+ T cells to test effects on T cell function. Although PDK1 and PDP1 were expected to influence PDH in opposing directions, by several criteria they induced similar changes relative to control T cells. Seahorse metabolic flux assays showed both groups exhibited increased glycolysis and oxidative phosphorylation. Both groups had improved primary and memory recall responses following infection with murine gammaherpesvirus-68. However, metabolomics using labeled fuels indicated differential usage of key fuels by metabolic pathways. Importantly, CD8+ T cell populations after B cell lymphoma challenge were smaller in both groups, resulting in poorer protection, which was rescued by glutamine and acetate supplementation. Overall, this study indicates that PDK1 and PDP1 both enhance metabolic capacity, but the context of the antigenic challenge significantly influences the consequences for T cell function.

Authors

Taewook Kang, Young-Kwang Usherwood, Julie A. Reisz, Sukrut C. Kamerkar, Rachel Culp-Hill, Owen M. Wilkins, Andreia F. Verissimo, Fred W. Kolling IV, Anton M. Hung, Shawn C. Musial, Pamela C. Rosato, Angelo D’Alessandro, Henry N. Higgs, Edward J. Usherwood

×

Figure 8

CD8+ T cells overexpressing PDH regulatory enzymes show compromised efficacy against tumor challenge.

Options: View larger image (or click on image) Download as PowerPoint
CD8+ T cells overexpressing PDH regulatory enzymes show compromised effi...
(A) B6 mice received 300,000 EμMyc-OVA B cell lymphoma cells expressing luciferase by intraperitoneal injection. Then, 4 days later, 25,000 transduced CD8+ T cells (EV/Pdk1/Pdp1) were adoptively transferred into B lymphoma–bearing mice. (B) In vivo IVIS imaging of mouse tumors over the course of 32 days. (C) Kaplan-Meier survival analysis of the tumor-bearing mice showing significant reductions in PDK1 (P = 0.0064 Mantel-Cox log-rank test) and PDP1 (P = 0.0316) groups compared with EV. (D) Flow cytometry analysis of OT-I cells in vivo. A total of 1 million EμMyc-OVA tumor cells were injected into B6 mice, followed by 500,000 transduced OT-I CD8+ T cells 4 days later. T cells were analyzed by flow cytometry 6 days after adoptive transfer. (E) Apoptosis and cell death marker staining of OT-I cells from inguinal lymph nodes of the B cell lymphoma model. Experiments were repeated 2 times. n = 5–10 biologically independent samples per group; 1-way ANOVA corrected for multiple comparisons with Tukey’s multiple comparisons test. *P < 0.05; **P < 0.01; ****P < 0.0001. Data are mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts